Clinical trials
PSMA clinical trials
Below are recruiting psma clinical trials, each written for real people, not researchers. We’re tracking 197 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04637503RecruitingPhase 1/Phase 2
CAR-T therapy for neuroblastoma targeting three markers
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Shenzhen, GuangzhouAges 1–65 - NCT04951817Recruiting
PSMA PET/CT scan to assess Ra-223 treatment in advanced prostate cancer
This trial studies whether a special whole-body scan (PSMA PET/CT) can help assess how well Ra-223 (a targeted treatment) may work in men with advanced prostate cancer that has spread to the bones. It may help doctors choose and plan Ra-223 treatment more effectively.
Taoyuan CityAges 40–85 - NCT05000827Recruiting
PSMA PET scan to guide lymph node surgery in prostatectomy
This study tests whether a special prostate scan called PSMA PET/CT can help doctors decide which pelvic lymph nodes to remove during prostate surgery. It may improve who needs lymph node surgery by using scan results to guide the operation.
Nijmegen, GelderlandAges 18 years+ - NCT05324332Recruiting
Two scans to study prostate cancer in the same group
This trial looks at prostate cancer patients who have not started treatment yet and have two different PET/CT scans close together. It may help doctors compare how these scans show prostate cancer in the body.
Beijing, Beijing MunicipalityAges 18–90 - NCT05381103RecruitingPhase 2/Phase 3
PSMA scan to plan prostate surgery and help protect erections
This trial tests whether using a PSMA-PET scan before prostatectomy can guide surgery in a way that helps preserve sexual function. It may be most helpful if you have certain kinds of prostate cancer and want to keep erections after surgery.
Indianapolis, IndianaAges 40–80 - NCT05520255RecruitingPhase 3
PSMA PET/CT scan to guide care after prostate cancer treatment
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
Edmonton, AlbertaAges 18 years+ - NCT05521412RecruitingPhase 1/Phase 2
PSMA-targeted radioligand for advanced prostate cancer
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Melbourne, VictoriaAges 18 years+ - NCT05547919Recruiting
PSMA scan study for newly diagnosed gut cancer
This study looks at a specific body scan target (PSMA) in newly diagnosed gut cancers to better understand the tumor and guide future care. You may be asked to provide tumor tissue and get a PSMA PET/CT scan, and the results could help identify who may benefit from PSMA-based treatments.
Würzburg, BavariaAges 18 years+ - NCT05562791RecruitingPhase 1
Testing PSMA PET/CT scans for metastatic bladder or skin cancer
This Phase 1 study tests how well a PSMA PET/CT scan can find cancer spots in people with metastatic bladder cancer (urothelial cancer) or metastatic melanoma. It may help doctors better see where cancer is and guide next steps.
Basking Ridge, New JerseyAges 18 years+ - NCT05582876Recruiting
PET/MR scan to plan personalized prostate cancer treatment
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
BialystokAges 18–99 - NCT05656573RecruitingPhase 1
Study of PSMA-targeted CAR T for advanced prostate cancer
This Phase 1 study tests a type of immune cell treatment (CAR T) made to recognize PSMA, a marker on prostate cancer cells. It’s for advanced prostate cancer and aims to find a safe dose and how well the treatment works.
BeijingAges 35–85 - NCT05761366RecruitingPhase 2
18F-PSMA PET/CT scan for PSMA-positive tumors
This Phase 2 study tests an imaging scan called 18F-PSMA PET/CT to find tumors that have a specific marker (PSMA). It may help doctors better locate and evaluate PSMA-positive cancers.
Beijing, ChaoyangAges 18 years+ - NCT05766371RecruitingPhase 2
Pembrolizumab plus PSMA-targeted therapy for advanced prostate cancer
This Phase 2 trial tests whether adding pembrolizumab to a PSMA-targeted drug can better treat metastatic prostate cancer that has progressed despite hormone-blocking treatments. It may help some people by attacking PSMA-positive cancer spots seen on a special PET scan.
San Francisco, CaliforniaAges 18 years+ - NCT05847166Recruiting
Testing a PSMA-targeted treatment for prostate cancer
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
Bydgoszcz, PolandAges 18 years+ - NCT05847348RecruitingPhase 3
PET scan for rising PSA after prostate cancer treatment
This Phase 3 trial tests whether a special PET scan using 68Ga-PSMA-11 can detect prostate cancer that has returned after surgery or radiation, measured by rising PSA. If the scan works well, it may help doctors find where the cancer is coming back.
BeijingAges 18 years+ - NCT05893381RecruitingPhase 2
Targeted PSMA scan plus focused radiation vs radiation alone
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Cesena, FCAges 18 years+ - NCT06003556RecruitingPhase 2
PSMA-guided ablation for prostate cancer
This trial tests a targeted treatment for prostate cancer using PSMA imaging to guide ablation (removal) of the tumor. It may help men with early-stage, localized cancer that hasn't spread.
Calgary, AlbertaAges 50 years+ - NCT06122584RecruitingPhase 3
PSMA PET scan for high-risk prostate cancer before surgery
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
NancyAges 18 years+ - NCT06145633RecruitingPhase 2
Vorinostat and 177Lu-PSMA-617 for PSMA-Low prostate cancer
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
Seattle, WashingtonAges Any age - NCT06167629Recruiting
PSMA PET scan study for prostate cancer
This study uses a special type of PET scan called PSMA PET to better understand and track prostate cancer. The scan helps doctors see where the cancer is in the body and if treatment is working.
MilanAges 18 years+ - NCT06209853Recruiting
PSA levels and PSMA PET/CT in prostate cancer
This study looks at how PSA levels (a blood test marker for prostate cancer) relate to images from a special scan called F-18 PSMA PET/CT. It helps doctors understand what the scan results mean for your cancer.
AsyutAges Any age - NCT06216249RecruitingPhase 2
Flexible dosing of Lu-PSMA for advanced prostate cancer
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06220188RecruitingPhase 2
PSMA therapy for prostate cancer that has come back
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
ViennaAges 18–80 - NCT06259123RecruitingPhase 2
PSMA Radiotherapy Before Prostate Cancer Surgery
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
ViennaAges 18–75
Hear when a new PSMA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma?
- Yes. Clin2 currently lists 197 recruiting psma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.